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Evaluering av behandlingseﬀekt i kreft ved
MR avbildning og spektroskopi
Arbeidet i denne avhandlingen presenterer et sett utfyllende MR metoder
som kan brukes for å studere eﬀekt av kreftbehandling. Motivasjonen er
blant annet å kunne tilby skreddersydd behandling for hver enkelt pasient.
Pasienter med lokalavansert brystkreft får ofte behandling med kjemoterapi
i forkant av kirurgi for å redusere tumorstørrelse og utbredelse av såkalt
primær inoperabel sykdom. Det er stor variasjon i behandlingsrespons for
denne pasientgruppen, og det er derfor behov for metoder som kan forutsi
eller tidlig detektere behandlingseﬀekt, slik at behandlingen kan tilpasses in-
dividuelt. Arbeidet i denne avhandlingen viser at eﬀekter av kreftbehandling
kan detekteres med MR allerede etter en behandling, og fremstår dermed
som et lovende verktøy ved kreftbehandling.
I dette arbeidet ble forandringer i blodgjennomstrømningen i tumor påvist
med dynamisk kontrastoppladet MR avbildning, både i tumormodeller for
brystkreft behandlet med kjemoterapi og i tumormodeller for tykktarmkreft
påvirket av fettsyren TTA. Forandringer ble også funnet for brystkreft-
pasienter behandlet med kjemoterapi. I tillegg ble det funnet en sammen-
heng mellom dynamisk kontrastoppladet MR ved diagnosetidspunktet og 5
års overlevelse for brystkreftpasienter, noe som viser at MR også kan ha
prognostisk verdi for denne pasientgruppen. I dynamisk kontrastoppladet
MR avbildning brukes økningen i signalintensiteten i en serie MRbilder før
og etter intravenøs injeksjon av kontrastmiddel til å studere vev med økt
blodgjennomstrømning, som tumorvev.
Videre ble det observert lavere relative nivåer av metabolitten kolin målt med
MR spektroskopi av behandlede tumormodeller for brystkreft, sammenlignet
med ubehandlede tumorer. Metabolitter er små molekyler som inngår i
cellenes stoﬀskifte, og kan studeres med MR spektroskopi både før og etter
tumoren er operert bort. Kolinforbindelser blir ofte brukt som tumormarkør,
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iv
og kan gi viktig informasjon om mekanismer ved behandlingsrespons.
Den tilsynelatende diﬀusjonskoeﬃsienten i tumor ble beregnet fra diﬀusjonsvek-
tede MR bilder i brystkreftpasienter, og økte etter kjemoterapi. Dette
ble også vist i en studie av tumormodeller i brystkreft. Diﬀusjonsvektet
MR avbildning utnytter de naturlige bevegelsene til vannmolekyler, og kan
brukes til å studere egenskaper i tumor på cellulært nivå. Diﬀusjon av van-
nmolekyler i vev er begrenset av strukturer som cellemembraner og makro-
molekyler, og kan brukes til å detektere forandringer i for eksempel celletet-
thet.
Forskningsarbeidet består av ﬁre deler, to studier av tumormodeller i mus,
og to studier av brystkreftpasienter. Både MR protokoller og metoder for
analyse av data ble etablert, og prinsipper fra dyreforsøkene ble overført til
pasientstudiene. Dynamisk kontrastoppladet MR ble analysert ved hjelp av
en farmakokinetisk modell for kontrastmiddelet, og MR spekter ble analy-
sert med multivariate analysemetoder. Tre av studiene er publisert i inter-
nasjonale tidsskrifter, og den siste er innsendt for vurdering.
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Summary
Breast cancer patients with locally advanced disease are often treated with
chemotherapy prior to surgery, to downstage primary inoperable disease.
There is a large variation in treatment response between patients, and meth-
ods that can predict or early detect treatment eﬀects are needed to optimize
therapy individually.
Magnetic resonance (MR) has evolved as an important diagnostic tool in
oncology, both for detection and followup in the course of treatment. Sev-
eral MR methods are often used during one examination, providing both
detailed anatomical images and functional images of perfusion, water diﬀu-
sion or metabolic information. In dynamic contrast enhanced (DCE) MRI a
series of images are acquired before and after intravenous injection of a con-
trast agent, demonstrating an increase in signal intensity of highly perfused
tissues as in tumors. The formation of new blood vessels is an important step
in tumor progression, and aggressive tumors are often highly vascularized.
Thus DCEMRI has potential for in vivo imaging of tumor blood supply,
and functional changes may be assessed. Diﬀusion weighted (DW) MRI ex-
ploits the natural diﬀusion of water molecules, and may be used to study
tumor properties at a cellular level. The motion of water molecules in tis-
sue is restricted by structures such as cell membranes and macromolecules,
and DWMRI may be used to detect changes in e.g. cell density. Metabolic
information can be studied both with in vivo MR spectroscopy (MRS) be-
fore the tumor is resected, and with ex vivo MRS of tumor biopsies. MR
signals from small metabolites as choline compounds are used to study tu-
mor metabolism, and may give important information on treatment response
mechanisms.
The aim of this work was to use a combination of MR methods to assess
treatment response both in preclinical human tumor models in mice and in
breast cancer patients undergoing neoadjuvant chemotherapy (NAC). Both
vii
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in vivo MR protocols and methods for analysis of the data were established
during this work. Overall, diﬀerences in tumor vascularity were detected
with DCEMRI, both in breast cancer xenografts treated with chemotherapy
and in colon cancer xenografts inﬂuenced by the fatty acid TTA. Changes in
response to chemotherapy were also found with DCEMRI in breast cancer
patients, in addition to a correlation between parameters after DCEMRI
before treatment with overall survival. The apparent diﬀusion coeﬃcient
derived from DWMRI in breast cancer patients appeared to increase after
one cycle of chemotherapy, as was also found in a study of breast cancer
xenografts. In addition, treated breast tumor models had lower levels of
choline compounds when compared to controls, as measured with MRS.
Overall, the work in this thesis presents a useful set of complementary MR
methods, well suited for treatment monitoring.
Symbols and abbreviations
α ﬂip angle
ADC apparent diﬀusion coeﬃcient
AIF arterial input function
AUC area under the curve
b diﬀusion weighting factor
C contrast agent concentration
Cp plasma concentration
Ct tissue concentration
D dose of contrast agent
DCE dynamic contrast enhanced
DW diﬀusion weighted
EES extravascular extracellular space
FEC 5ﬂuorouracil, epirubicin and cyclophosphamide
FLASH fast low angle shot
FOV ﬁeld of view
HR MAS high resolution magic angle spinning
IAUC initial area under the curve
IDC inﬁltrating ductal carcinoma
ILC inﬁltrating lobular carcinoma
ICA independent component analysis
Ktrans transfer constant
KNN kohonen neural network
LDA linear discriminant analysis
MRI magnetic resonance imaging
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xMRS magnetic resonance spectroscopy
NAC neoadjuvant chemotherapy
PCA principal component analysis
PLS partial least squares regression
PNN probabilistic neural network
ppm parts per million
PRESS point resolved spectroscopy
r1 relaxivity
RSI relative signal intensity
SE spin echo
SI signal intensity
T1 longitudinal relaxation time
T2 transversal relaxation time
TE echo time
TR repetition time
TTA tetradecylthioacetic acid
TTP time to peak
ve volume fraction of extravascular extracellular space
vp volume fraction of plasma
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Chapter 1
Introduction
1.1 Cancer
In Norway, more than 25.000 patients are diagnosed with cancer each year,
and one fourth of all deaths are caused by cancer1. Optimal treatment of
the disease is important both for patients and for socioeconomic reasons.
The trend moves toward individualized therapy, where each patient receive
tailored treatment for their disease. In this setting, tumor markers of both
predictive and prognostic value are important, and also methods to monitor
treatment response are needed.
Cancer is thought of as a monoclonal disease, i.e. a tumor has developed
from a single cell. An accumulation of mutations in DNA aﬀecting prolifer-
ation and anti proliferation genes, is transforming human cells into immortal,
rapidly growing cancer cells that show little celltocell interactions. Gen-
erally, cells need blood supply to grow, thus for solid tumors, growth is
restricted by the diﬀusion distance of oxygen in tissue. The ability to re-
cruit new blood vessels is crucial in tumor progression, and is termed the
neoagniogenic switch (Folkman, 1971; Carmeliet and Jain, 2000). This re-
sults in formation of a chaotic and abnormal vascular network, where vessels
can lack basement membrane and are highly permeable. Tumors often have
high cell density, high ﬂuid pressure, and permanent or ﬂuctuating hypoxia,
which makes treatment challenging, and tumors become lethal when devel-
oping to inﬁltrating and metastatic disease.
1Statistics Norway, http://www.ssb.no
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Figure 1.1: Anatomy of the breast, showing lobes and ducts inside the breast. The
lymph nodes near the breast are also shown. Adapted from Don Bliss, National
Cancer Institute (NCI).
1.2 Breast cancer
Breast cancer is the most frequent cancer type in women, with more than
2700 reported cases in Norway each year (Bray, 2008). The most common
type of breast cancer is carcinomas, developing from epithelial cells in the
ducts of the breast as inﬁltrating ductal carcinoma (IDC), or the lobules
of the breast as inﬁltrating lobular carcinoma (ILC), see Figure 1.1 for the
anatomy of the breast. Clinical examination, mammography and pathologic
examination of ﬁne needle aspiration cytology or core biopsy deﬁnes the basis
for diagnosis of breast cancer. In addition, important prognostic factors are
tumor size and grade, lymph node metastases, estrogen and progesterone
receptor status, and proliferative index (Ki67/MIB1). Following the TNM
system for malignant tumors, the disease is classiﬁed by tumor size (T),
grade of axillary lymph node involvement (N) and distant metastases (M),
as described in Sobin and Wittekind (2009). Combinations of these factors
deﬁnes the tumor stage, from small primary tumors (< 2cm, Stage I) to
locally advanced disease (Stage III) and distant metastases (Stage IV).
Approximately 10% of breast cancer patients are diagnosed with locally ad-
vanced disease, which is deﬁned as primary inoperable cancer. This diagno-
sis includes large tumors and/or involvement of axillary lymph nodes. The
5year progression free survival for these patients is around 30%, however
substansial better prognosis is expected for stage III compared to stage IV
1.2. Breast cancer 3
(Figure 1.2). The last decades there has been an increase in relative survival
for breast cancer patients in general, however, for metastatic disease (stage
IV) this is not the case. A combination of better treatment and a national
program for mammography screening are possible explanations for the trend
to improved survival.
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Figure 1.2: Survival for breast cancer patients by stage. (A) Trends in 5year
relative survival, and (B) Longterm relative survival. From Småstuen et al. (2008).
1.2.1 Neoadjuvant chemotherapy
Patients with locally advanced breast cancer are treated with chemother-
apy before surgery, termed neoadjuvant chemotherapy (NAC). It has been
shown that this is equivalent with traditional adjuvant chemotherapy ad-
ministered after surgery, when comparing disease free and overall survival
(Rastogi et al., 2008). Furthermore, the treatment eﬀect can be evaluated
and optimized, and early systemic treatment would also beneﬁt treatment of
micrometastatic disease. The trend moves toward including patients with
tumors of lower stage for NAC as well, to increase the possibility for breast
conservation surgery.
In Norway, the standard therapy is a combination of the cytostatic agents 5
ﬂuorouracil, epirubicin and cyclophosphamid (FEC). After four cycles, the
treatment eﬀect is evaluated by measurement of tumor size, and treatment
is changed to taxanebased treatment when tumor response is insuﬃcient.2
The taxane docetaxel is produced from the needles of the European yew tree,
an important group of cytostatica developed in the 1990s.The mechanism
2Norwegian breast cancer group, http://www.nbcg.no
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of action is binding to and impairing the dynamics of microtubuli, causing
apoptosis and cell death. Docetaxel has been shown to enhance response
to NAC in breast cancer patients (Smith et al., 2002), however there is
large variations between patients in response rates and there is a need for
predictive factors to identify tumors that are sensitive to this agent (Noguchi,
2006).
1.3 Colon cancer
The most common type of colon cancer is adenocarcinoma, originating from
epithelial cells in mucosa in the colon (Figure 1.3). The initial stage is often
manifested as adenomatous polyps. In Norway a total of 3400 new cases of
colorectal cancer were diagnosed in 2007, and the incidence has increased the
last 50 years (Bray, 2008). Colonoscopy with biopsy is the most important
method for diagnosis, however CT, ultrasound and MRI are often used in the
further diagnostic assessment. Early stages and localized cancer is treated
with surgery, while locally advanced disease is treated with NAC followed
by surgery, and radiotherapy.3
Figure 1.3: Anatomy of the colon and rectum. Printed with permission. ( c©2005
Terese Winslow, U.S. Govt. has certain rights.)
3Oncolex, http://www.oncolex.no
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1.3.1 Dietary fatty acids
Diet has been proposed as an important risk factor in the development of
colon cancer. A diet high on animal fat and low on ﬁber, fruit and vegetables
is thought to increase the risk. Special attention has been given n3 poly-
unsaturated fatty acids found e.g. in marine oils, as protective agents for
development of cancer (Bartsch et al., 1999; Tsubura et al., 2009). Studies
of the synthetic fatty acid tetradecylthioacetic acid (TTA) has also shown
growth inhibitory eﬀect on malignant cancer cell lines from breast, glioma
and leukemia (Berge et al., 2003; Abdi-Dezfuli et al., 1997; Tronstad et al.,
2002; Berge et al., 2001). The metabolic eﬀects of TTA has been reviewed
(Berge et al., 2002).
1.4 Human tumor xenografts
Commonly used model systems for human cancer is transplanting human
tumor cells or tissue to immunodeﬁcient mice, to form a xenograft. Often
the tumor is transplanted under the skin of the animal, but methods for
transplantation to the site of origin has also been developed. The implanted
tumor cells will trigger neoangiogenesis from the host tissue, and continue to
grow into a tumor mass, as an `animal culture' (Frese and Tuveson, 2007).
The model systems retain many characteristics from its native tumor, as
histological properties and response characteristics. However, the stromal
tissue is of mouse origin, and care has to be taken when generalizing to
human tumors. Nevertheless, the number of publications based on tumor
mouse models has increased exponentially the last two decades (Krupke
et al., 2008), showing the importance of such models for several research
areas like development of new treatments, understanding molecular mech-
anisms, and developing methods for characterizing and monitoring tumor
progression.
1.5 Magnetic resonance imaging
Magnetic resonance imaging (MRI) emerged as a clinical available method
in the early 1980s, however the principles of magnetic resonance was dis-
covered as early as 1946 by Bloch (1946) and Purcell et al. (1946). By use
of a strong external magnetic ﬁeld, magnetic gradients and radio frequent
6 Introduction
Figure 1.4: MR images from a breast cancer patient, a T2weighted image (A),
diﬀusion weighted image (B) and an ADCmap calculated from the diﬀusion
weighted images (C). On the right side, a T1weighted image (D), a subtraction
image after contrast agent injection (E), and a projection of the maximum signal
intensity of the subtraction image volume (F).
electromagnetic radiation, protons in the body is stimulated to release sig-
nals detectable by coils. There is no documented biological side eﬀects, and
MRI has evolved as an important method for diagnostic assessment of solid
cancer. With MRI, diﬀerent type of contrast of the tissue can be obtained
by exploiting diﬀerent magnetic properties of protons, as proton density,
longitudinal relaxation rate (T1) and transversal relaxation rate (T2). An
example of the diﬀerence in contrast of T1 and T2weighted images from a
breast cancer patient is demonstrated in Figure 1.4.
In addition to superior anatomical images, functional images can also be ob-
tained by MRI. The most important techniques for imaging of malignancies
1.5. Magnetic resonance imaging 7
are dynamic contrast enhanced MRI (DCEMRI), diﬀusion weighted MRI
(DWMRI) and chemical shift imaging.
1.5.1 Dynamic contrast enhanced MRI
In T1weighted dynamic contrast enhanced MRI a series of identical images
is acquired before and after intravenous injection of a contrast agent. The
paramagnetic contrast agent is distributed through the blood, and leaks out
in highly vascularized tissue, especially cancer tissue. An example of a series
of contrastenhanced images in a breast cancer patient are shown in Figure
1.5, with signal intensity variation over time. Dynamic contrast enhanced
MRI has been used for imaging in breast cancer since late 1980s (Kaiser
and Zeitler, 1989), and was early used to diﬀerentiate between benign and
malignant disease, and correlated well to pathologic tumor size (Gribbestad
et al., 1992). It is generally accepted that injection of a contrast agent is
essential to diﬀerentiate tumor tissue from parenchyma, and it is therefore
included in standard MRIprotocols for breast cancer. DCEMRI is used
to diﬀerentiate benign from malignant disease, staging, screening of patients
at high risk, monitoring treatment response, and followup after surgery
and radiotherapy (Turnbull, 2009). Guidelines for breast MRI have been
proposed by the European Society of Breast Imaging (Mann et al., 2008).
For colon cancer, DCEMRI has been of minor use in detection and staging.
However, more attention has been paid to the evaluation of treatment eﬀect,
in particular to antiangiogenic agents (Goh et al., 2007). In addition, DCE
MRI has been shown to correlate to immunohistochemical markers for tumor
angiogenesis (Zhang et al., 2008).
Contrast agents used in the clinics are often paramagnetic Gadolinium com-
plexes, as the extracellular tracer gadodiamide (OmniscanTM, GE Health-
care), which operates by shortening of the longitudinal relaxation rate (T1),
hence increasing the signal in T1weighted images. Several imaging se-
quences can be used for dynamic contrast enhanced imaging, of these the
spin echo sequence has the advantage of a linear relationship between signal
intensity and contrast agent concentration (Larsson et al., 1990), although
this is a time consuming method. The signal intensity (SI) for a spinecho
sequence follows the equation
SI ∝ ρ · (1− e−TR/T1) · e−TE/T2 , (1.1)
where ρ is the proton density, TR the repetition time, TE the echo time,
and T2 is the transverse relaxation rate. By choosing a short echo time, the
8 Introduction
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Figure 1.5: (A) Dynamic contrast enhanced MRI series of an MCF7 xenograft at 7
Tesla. The ﬁrst T1weighted image has low contrast, however after contrast agent
injection the vascular tumor tissue lightens up. At the end of the sequence contrast
agent has diﬀused into necrotic areas, which can be seen as high intensity areas.
(B) A contrast enhanced image 1.6 min. after contrast agent injection. Three
voxels are encircled, with corresponding enhancement curve in (C), showing viable
tumor tissue (1 and 2) and necrotic tissue (3).
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sequence will be T1weighted. To improve temporal resolution and increase
the imaging matrix, the Fast Low Angle Shot (FLASH) sequence has been
used frequently in the clinical setting, with signal intensity described by
SI ∝ ρ sinα · 1− e
−TR/T1
1− cosα · e−TR/T1 · e
−TE/T ∗2 , (1.2)
where α is the ﬂip angle and T ∗2 is the apparent transverse relaxation rate.
When the echo time is suﬃciently lower than T ∗2 , this sequence will also be
T1weighted. This is especially well suited for fast imaging of 3D volumes.
For a ﬁxed TR and T1 the sequence has its highest signal intensity at Ernst
angle. However, to maximize sensitivity to changes in T1, the optimal ﬂip
angle, α1 can be found from the relationship
cos(α1) =
2e−TR/T1 − 1
2− e−TR/T1 . (1.3)
The T1 relaxation rate after injection of contrast agent is related to the
contrast agent concentration (C) and relaxivity (r1) by
1
T1
=
1
T10
+ r1 · C, (1.4)
where T10 is the longitudinal relaxation rate without contrast agent. This
precontrast relaxation rate can be measured in several ways, e.g. by varying
the repetition time in the spin echo sequence (1.1) or varying the ﬂip angle
in the FLASH sequence (1.2). Thus the concentration of contrast agent in
tissue can be derived.
1.5.2 Analysis of DCE-MRI
Dynamic contrast enhanced imaging has been used to assess the vascularity
of tumor tissue, by using pharmacokinetic modeling of the contrast agent
concentration (Larsson et al., 1990; Tofts and Kermode, 1991). These meth-
ods have been derived from studies using freely diﬀusible tracers to measure
blood ﬂow (Kety, 1960), where tissue is modeled by two compartments, the
intravascular space and the extravascular extracellular space (EES). When
the contribution to the contrast agent concentration in an MRI voxel is
assumed to come from both tissue (Ct) and blood plasma (Cp), the two
compartment model can be expressed as
Ct(t) = vpCp(t) +Ktrans
∫ t
0
Cp(t′)eK
trans(t−t′)/vedt′, (1.5)
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Figure 1.6: The pharmacokinetic model assumes two compartments in a MRI voxel:
The plasma (vp) and the extracellular extravascular space (ve). The concentration
of contrast agent is Cp and Ct, respectively. The extraction fraction of contrast
agent over the vessel wall is given by Ktrans.
where vp is the volume fraction of blood plasma, ve is the volume fraction
of tissue space available for contrast agent (EES for the extracellular tracer
gadodiamide), and Ktrans is the transfer constant between blood plasma and
EES, see Figure 1.6. The transfer constant is dependent on several physio-
logical conditions, e.g permeability and blood ﬂow. In tumors, we assume
the model is limited by both ﬂow and permeability surface area product,
giving the relation Ktrans = EFρ(1−Hct), where E is the extraction ratio,
F is the ﬂow of whole blood per unit mass of tissue, and Hct is Hematocrit.
A consensus for pharmacokinetic analysis of DCEMRI was proposed by
Tofts et al. (1999).
The concentration in blood plasma, the arterial input function (AIF), is
often assumed to follow a biexponential decay, as described by
Cp(t) = D · (a1e−m1t + a2e−m2t), (1.6)
where D is the injected contrast agent dose, a1 and a2 are the amplitudes
of the components, and m1 and m2 are their rate constants. The fast com-
ponent of the function comes from the exchange of contrast agent between
plasma and EES, while the slow component is renal secretion of contrast
agent. The AIF may be derived from arteries in the DCEMRI series di-
rectly, and provides the best input to the analysis. However, population
based AIF parameters are widely used, especially on clinical data, due to
diﬃculties with deﬁnition of arteries, partial volume eﬀects and other prac-
tical considerations.
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In clinical practice, a DCEMRI examination can be subjectively evaluated
by review of the signal intensity time curves. Each curve may be classiﬁed
based on curve shape, as proposed by Daniel et al. (1998). Other empirical
methods with no assumptions are also frequently used for analyzing DCE
MRI. The relative signal intensity (RSI) is calculated as the fraction of signal
intensity at a speciﬁed time after contrast agent injection, to the baseline.
The area under the signal enhancement curve is often calculated for the
ﬁrst two minutes after contrast agent injection (initial area under the curve,
IAUC), or for the total time series (AUC). The time to peak (TTP) is the
time from contrast agent injection to the maximum signal intensity, and is
also a parameter used for characterizing the contrast enhancement curves.
Multivariate methods has also been proposed as a modelfree tool for DCE
MRI analysis, in combination with curve types as a diagnostic tool (Eyal
and Degani, 2009; Eyal et al., 2009).
1.5.3 Diﬀusion weighted MRI
Diﬀusion weighted MRI (DWMRI) exploits the natural random motion of
water molecules. In tissue, this motion is restricted by cellular packing,
intracellular elements, membranes and macromolecules (Figure 1.7). The
method is extensively used for assessment of intracranial disease, where early
changes are detected before visibly abnormality can be seen. The method
has also evolved as promising in oncology, and technological developments
has made DWMRI of the body available (Koh and Collins, 2007). Solid
tumors often separates from normal tissue with high cellularity and macro-
molecular structure, thus water is more restricted and gives higher intensities
in DWMRI. Structures at the cellular level can be assessed using diﬀusion
sensitizing gradients (Stejskal and Tanner, 1965; Bammer, 2003). The MR
signal (SI) in a diﬀusion weighted image can be expressed by
SI = SI0 · e−b·ADC, (1.7)
where SI0 is MR signal without diﬀusion sensitization, ADC is the appar-
ent diﬀusion constant (s/mm2), and b is termed the bvalue, reﬂecting the
grade of diﬀusion weighting. The bvalue depends on the strength and the
duration of the gradients in the sequence. The diﬀusion gradients are usu-
ally applied in three orthogonal directions to average potential anisotropy, a
measurement termed trace. A consensus on DWMRI in cancer has been
proposed, but the need for more work for standardizing and validating the
method is emphasized (Padhani et al., 2009).
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Figure 1.7: Principles of diﬀusion of water in tissue. (A) In tissue with high
cellularity, as in tumors, there is a high grade of restricted diﬀusivity of water
molecules (black dots). (B) After an eﬀective treatment the cellularity is reduced
from apoptosis and necrosis, and the diﬀusivity increases. (Koh and Collins, 2007)
1.6 Magnetic resonance spectroscopy
Magnetic resonance spectroscopy (MRS) is a method used to obtain infor-
mation about molecules. The most common nucleus used for MRS is 1H,
however 13C, 19F and 31P are also frequently used in analysis of cell cul-
tures, tissue biopsies, animals and humans. The natural abundance and the
appearance in biological tissue is of importance when choosing nucleus of in-
terest, together with high sensitivity, which makes 1H a good candidate for
MRS. When placed in a high magnetic ﬁeld, protons have a resonance fre-
quency proportional to the magnetic ﬁeld. In addition, the chemical environ-
ment will also inﬂuence this frequency, thus protons from diﬀerent chemical
compounds can be separated in a spectrum. Furthermore, protons closely
located can inﬂuence each other, resulting in splitting of the peaks. After ac-
quiring a spectrum from a sample, the frequency of the peaks are calculated
as parts per million (ppm) of the frequency of a standard, and the peaks are
assigned to molecules. In biological tissue, amino acids, glucose, lactate, cre-
atine and choline are available with 1H MRS. The metabolic ﬁngerprint of a
wide range of cancers has been investigated, and metabolomics has evolved
as a current and potential method for diagnosis, prognosis and therapeutic
evaluation in oncology (Spratlin et al., 2009).
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1.6.1 In vivo MRS
In vivo MRS can be performed in the same imaging session as MRI. The
most common method is single voxel point resolved spectroscopy (PRESS),
which uses three slice selective pulses (90◦−180◦−180◦) to localize the signal
from a deﬁned volume. For spectroscopy, it is crucial with a homogeneous
magnetic ﬁeld, thus a good shim is important when acquiring spectra. In
addition, moving to higher ﬁeld strengths especially beneﬁts in vivo MRS,
as the separation between metabolites is proportional to the magnetic ﬁeld.
The resolution is limited for in vivo MRS, however metabolites such as the
total choline peak and lactate may be detected and used as biomarkers for
breast cancer (Figure 1.8). The poor resolution is also a consequence of
aniotropic interactions between molecules in tissue, where molecular motion
is restricted. In solutions, the eﬀect of these interactions are averaged by
random molecular motion.
1.6.2 Ex vivo high resolution magic angle spinning MRS
MRS examinations of tumor biopsies can be performed with high magnetic
ﬁeld spectrometers, however the deﬁned structures in the samples will reduce
the spectral resolution as for in vivo MRS. By spinning the sample at a magic
angle to the external magnetic ﬁeld (54.7◦) the anisotropic interactions is
canceled out, producing peaks that are comparable with the resolution for
liquids. This has become a valuable method for analyzing biological tissue
like tumor samples (Sitter et al., 2009), and is termed high resolution magic
angle spinning (HR MAS). The tissue preparation is simple, the biopsy is
cut to ﬁt the MAS rotor, and a buﬀer with a reference compound is added
for shimming and chemical shift referencing. A single spectrum may contain
information from more than 30 metabolites (Sitter et al., 2002), and spectra
are often analyzed with multivariate analysis methods.
1.7 Multivariate analysis methods
Multivariate analysis methods are frequently used to analyze data consisting
of many variables. In MRS, the number of variables is often equal to the
number of points describing the spectra, often thousands. A large degree
of redundancy is expected for such data sets, and multivariate methods can
reduce the number of variables signiﬁcantly without loosing information.
14 Introduction
Creatine
total
Choline
Taurine
Glycine
Creatine
Water
Figure 1.8: Spectra from ex vivo HR MAS MRS (blue line) and in vivo MRS (red
line) of the same MCF7 breast cancer xenograft. The intensities are individually
scaled for the two spectra.
Principal component analysis (PCA) and independent component analysis
(ICA) are examples of unsupervised methods that decomposes the data ma-
trix into a set of components with associated score values for each sample.
The natural variation in a dataset can then be assessed without adding a
priori information. In supervised methods, information on e.g. class assign-
ment is used as input to the analysis, to emphasize the diﬀerence between the
classes. Methods as partial least squares regression (PLS), kohonen neural
networks (KNN), probabilistic neural networks (PNN) and linear discrimi-
nant analysis (LDA) are methods frequently used in chemometrics (Brereton,
2003).
Chapter 2
Objectives
The main objective of the research presented in this thesis are to apply MR
methods in the evaluation of treatment eﬀects in tumors. More speciﬁcally,
to:
• Establish a protocol for MR imaging and spectroscopy for experimental
tumor xenografts in mice.
• Investigate the feasibility of the MR methods for evaluating therapy
response in the tumor xenograft models.
• Implement similar methods for evaluation of tumor response during
neoadjuvant chemotherapy in breast cancer patients.
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Chapter 3
Materials and methods
An overview of the experimental setup and methods are given in Figure 3.1.
The methods will be shortly presented, additional descriptions can be found
in the publications IIV.
Paper I Paper II Paper III Paper IV
Human tumor xenograft Advanced breast cancer
Fatty acid: TTA Docetaxel Neoadjuvant chemotherapy
Dynamic contrast enhanced MRI
In vivo MRS
HR MAS MRS
Diffusion MRI
Kinetic + empirical KineticEmpiricalKinetic
Colon: SW620 Breast: MCF7
Growth assay
Histopathology
Histopathology
Histopathology
Histopathology
7 Tesla 1.5 Tesla 3 Tesla
Tumor 
type:
Treatment:
MR
Methods:
Other
Methods:
Figure 3.1: Schematic presentation of methods used in the papers presented in this
thesis.
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3.1 Tumor model systems
Model systems for colon and breast cancer was established in this thesis,
and were initiated by subcutaneously injection of the human tumor cells on
the hind leg of immunodeﬁcient mice (BalbC nu/nu). The breast cancer cell
line MCF7 was originally isolated from pleural eﬀusion in a woman with
malignant adenocarcinoma in 1970 (Soule et al., 1973), and was used as a
model system for breast cancer in Paper II. The colon cancer cell line used
in Paper I, SW620, was originally isolated from a lymph node metastasis
in a male patient diagnosed with colorectal adenocarcinoma in the early
1970's (Leibovitz et al., 1976). This cell line consists of individual small
spherical and bipolar cells lacking microvilli, and are highly tumorigenic
in nude mice. The cell lines used in the studies were purchased from the
American Type Culture Collection (ATCC), and cultured according to the
manufacturers recommendation. The colon cancer cell line was cultured at
the Department of Laboratory Medicine, Children's and Woman's Health,
NTNU. The animal experiments were approved by The National Animal
Research Authority.
The in vitro cell culture experiments in Paper I were done at the Section of
Medical Biochemistry, Institute of Medicine, University of Bergen.
3.2 Patients
Patients with primary inoperable breast cancer, undergoing neoadjuvant
chemotherapy at St Olavs Hospital, Trondheim, Norway, were enrolled in
the clinical studies. All patients signed written informed consent, and the
studies were approved by the institution's human ethics committee. Patients
included in paper III were enrolled in the period 19982001 and were followed
in minimum 5 years after diagnosis. For paper IV, patients were enrolled
in the period 20082009. Additional clinical information as tumor size, age,
and treatment, were obtained from the patient journals.
3.3 Preclinical MR protocols
For the tumor model systems in paper I and II, the MRI and in vivo MRS
were performed on a 7 Tesla Bruker BioSpec Avance 70/20 (Bruker Biospin,
Ettlingen, Germany) with a volume coil for transmitting and an actively
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Figure 3.2: (A) Image from a preclinical experiment on the 7 Tesla, with the
animal bed inside the magnet, and the tube for heated air fastened (1). (B) The
animal bed with coil, the tumor was placed under the surface coil (2), and the
coil was connected to the system with cables (3). (C) A mouse ready for scanning
with intravenous catheter placed in the tail vein (4), and the tumor bearing leg
stabilized in a stretchedout position (5).
decoupled quadrature surface coil (rat or mouse head) for receiving. The
mice were anastesized and an intravenous canule placed in the tail vein.
The mice were then ﬁxed on a dedicated animal bed with the surface coil
placed over the tumor on the leg, and then positioned in the isocenter of
the magnet. Body temperature was maintained by heated air ﬂow. The
experimental setup is shown in Figure 3.2. The MR protocols were op-
timized by use of phantoms, four tubes ﬁlled with agarose gel doped with
diﬀerent concentrations of gadodiamide. A series of spinecho images with
5 diﬀerent repetition times were acquired to calculate precontrast T1maps.
Only three slices were chosen to reduce the scan time. The T1weighted
sequence for DCEMRI was also a spinecho sequence, with identical ge-
ometry as the T1maps. Finally, the in vivo MRS in Paper II was acquired
with a PRESS sequence after automatic shimming. Water suppression was
optimized manually, and signal from outside the voxel was suppressed by
adding six suppression slices parallel to the surfaces of the voxel. Detailed
description of the MR protocols are given in Table 3.1.
The ex vivo HR MAS MRS was performed on a Bruker Avance DRX600
spectrometer (600 MHz) equipped with a 1H/13C MAS probe with gradient
aligned with the magic angle axis. The HR MAS protocol for ex vivo MRS
was adopted from work with breast cancer biopsies at our institution (Sitter
et al., 2002).
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Table 3.1: MR protocols used in the studies.
Paper I & II Paper III Paper IV
Field strength 7 Tesla 1.5 Tesla 3 Tesla
DWMRI 2D EPI
bvalues 50, 200, 500, 800
TR (ms) 5400
TE (ms) 86
NA 2
FOV 127×340
Matrix 72×192
Res. (mm2) 1.77×1.77
Slice (mm) 33.5
T1map 2D SE 3D FLASH
TR (ms) 150, 400, 1000, 2500, 4000 6
TE (ms) 7 2.45
α 2, 6, 10, 15
FOV (cm) 3×3 & 2×2* 18.7×25
Matrix 64×64 144×192
Res. (mm2) 0.47×0.47 & 0.31×0.31* 1.3×1.3
Slice (mm) 0.5 & 0.7* 2
DCEMRI 2D SE 3D FLASH 3D FLASH
TR (ms) 200 9 3.5
TE (ms) 7 3.8 1.14
α 30 10
FOV (cm) 3×3 & 2×2* 25×25 18.7×25
Matrix 64×64 256×256 144×192
Res. (mm2) 0.47×0.47 & 0.31×0.31* 0.98×0.98 1.3×1.3
Slice (mm) 0.5 & 0.7* 34 2
Temp. res. (s) 12.8 57 18.2
Repetitions 100 9 24
*Parameter in Paper I and II, respectively.
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Figure 3.3: (A) The breast coil made ready for clinical examination, with padding,
green disposable covers, and a pillow to rest the head. (B) A volunteer is lying on
the patient bed, ready to be placed in the magnet.
3.4 Clinical MR protocols
The MRI examinations in paper III were acquired on a 1.5 Tesla Picker
Edge system (Picker Edge EPI II, Cleveland, OH, USA) with a receive only
double breast coil. These examinations were data available from earlier
projects at our institution, and only the DCEMRI was analyzed. There
was no T1measurements from these examinations.
1
In Paper IV, a MAGNETOM Trio Tim 3 Tesla system (Siemens, Erlangen,
Germany) was used for MRI, with a dedicated bilateral 4channel breast
array coil for receiving. A canule was placed in the antecubital vein in the
patient's arm at arrival. The patients were lying in prone position during
the examinations with the breasts in the coil (Figure 3.3). The MR protocol
was optimized by use of waterﬁlled phantoms with gadodiamide, and vol-
unteers. Four bvalues were chosen for the DWMRI, 50, 200, 500 and 800
mm2/s. A 3D FLASH sequence with four diﬀerent ﬂip angles was chosen
for precontrast T1measurements, and this was also the sequence for DCE
MRI. In addition, a high resolution 3D volume was acquired before and after
the dynamic sequence. Detailed description of the clinical MR protocol is
given in Table 3.1.
1Projects by Kjell Arne Kvistad and Jana Rydland, Dept. of Radiology, St. Olav's
Hospital, Trondheim, Norway.
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3.5 Motion correction of DCEMRI
In Paper IV there were some severe cases of patient motion during DCE
MRI, probably caused by contraction of the pectoral muscle. To correct for
this, the misaligned images were registered to a chosen reference image by
use of FNIRT, a nonlinear image registration tool from the software package
FSL (Smith et al., 2004). Remaining misalignment was then removed by use
of independent component analysis using MELODIC 3.09 from the same
software package.
3.6 Data analysis
The image analysis was performed by use of inhouse analysis program de-
veloped in Matlab (The MathWorks Inc, Natick, MA, USA). DCEMRI
data in paper I, II and IV were analyzed with the twocompartment model
described in 1.5.2, while the empirical methods RSI and AUC were used in
paper I, II and III. Statistical analyses were performed in SPSS (SPSS Inc,
Chicago, IL, USA).
3.7 Histopathology
The histopathological examinations for paper I and II were done in collabora-
tion with the Department of Laboratory Medicine, Children's and Woman's
Health, NTNU. Staining for proliferation was done using Ki67, apoptotic
cells were stained with M30 cytodeath and endothelial cells were stained
with CD31 to detect blood vessels. In paper III and IV, standard clinical
histopathology was obtained from the patient journals.
Chapter 4
Summary of papers
Paper I
Eﬀect of dietary tetradecylthioacetic acid on colon cancer
growth studied by dynamic contrast enhanced MRI.
The purpose of this study was to evaluate the eﬀects of diets supplemented
with the modiﬁed fatty acid TTA and ﬁsh protein hydrolysate (FPH) on
tumor growth of the human colon cancer cell line SW620, and to investigate
the properties of tumor vasculature by dynamic contrast enhanced MRI in
a human tumor xenograft. In addition, MR protocol for imaging of tumor
xenografts was established.
SW620 cells were grown in vitro in presence of TTA and palmitic acid and
proliferation was measured by thymidine incorporation. The xenograft study
in mice was performed with four distinct diets: control diet, diet with TTA,
diet with TTA and FPH, and diet with FPH. SW620 cells were injected
subcutaneously, and dynamic contrast enhanced MRI was performed on a
Bruker BioSpec 7 Tesla system. The data was analyzed by twocompartment
modeling of the contrast enhancement, initial area under the curve and by
use of relative signal intensity distributions.
The in vitro cell studies revealed that TTA reduced tumor cell proliferation
as a function of both dose and time. The in vivo tumor growth was sig-
niﬁcantly reduced for the two groups fed TTA, as compared to the control
group. The mean 10th percentile RSI, ve and IAUC for the TTA group were
signiﬁcant higher than for the control group. This study conﬁrms the growth
inhibitory eﬀects of TTA, both in vitro and in vivo, in a colon cancer model.
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The analysis of DCEMRI data showed that TTA inﬂuences the vascular
properties of the tumor in addition to the growth.
Paper II
Assessment of early docetaxel response in an experimental
model of human breast cancer using DCEMRI, ex vivo HR
MAS and in vivo 1H MRS.
The purpose of this study was to evaluate the use of dynamic contrast
enhanced MRI, in vivo 1H MRS and ex vivo high resolution magic angle
spinning MRS of tissue samples as methods to detect early treatment eﬀects
of docetaxel in a breast cancer xenograft model (MCF7) in mice.
MCF7 cells were implanted subcutaneously in athymic mice and treated
with docetaxel (20, 30 and 40 mg/kg) or saline six weeks later. DCE
MRI and in vivo 1H MRS were performed on a 7 Tesla MR system three
days after treatment. The dynamic images were used as input for a two
compartment model, yielding the vascular parameters Ktrans and ve. HR
MAS MRS, histology and immunohistochemical staining for proliferation
(Ki67), apoptosis (M30 cytodeath) and vascular/endothelial cells (CD31)
was performed on excised tumor tissue. Both in vivo spectra and HR MAS
spectra were used as input for multivariate analysis (principal component
analysis and partial least squares regression analysis) to compare controls to
treated tumors.
Tumor growth was suppressed in docetaxel treated mice compared to the
controls. The antitumor eﬀect led to changes in the distributions of Ktrans
and ve in all the treated groups. Furthermore, in vivo MRS and HR MAS
MRS revealed a signiﬁcant decrease in choline metabolite levels for the
treated groups, in accordance with reduced proliferative index as seen on
Ki67 stained sections. In this study DCEMRI, in vivo MRS and ex vivo
HR MAS MRS have been used to demonstrate that docetaxel treatment of
a human breast cancer xenograft model results in changes in the vascular
dynamics and metabolic proﬁle of the tumor. This indicates that these MR
methods could be used to monitor intratumoral treatment eﬀects.
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Paper III
Predicting Survival and Early Clinical Response to Primary
Chemotherapy for Patients with Locally Advanced Breast
Cancer using DCEMRI.
The purpose of this study was to evaluate dynamic contrastenhanced MRI
as a tool for early prediction of response to neoadjuvant chemotherapy and
5year survival in patients with locally advanced breast cancer.
DCEMRI was performed in patients scheduled for NAC (n = 24) before and
after ﬁrst treatment cycle. Clinical response was evaluated after completed
NAC. Relative signal intensity and area under the curve were calculated from
the DCE curves and compared to clinical treatment response. Kohonen and
probabilistic neural network (KNN and PNN) analysis were used to predict
5year survival.
RSI and AUC were reduced after only one cycle of NAC in patients with
clinical treatment response (P = 0.02 and P = 0.08). The mean and 10th per-
centile RSI value before NAC were signiﬁcantly lower in patients surviving
more than 5 years compared to nonsurvivors (P = 0.05 and 0.02). This re-
lationship was conﬁrmed using KNN which demonstrated that patients who
remained alive clustered in separate regions from those that died. Calibra-
tion of contrast enhancement curves by PNN for patient survival at 5 years
yielded sensitivity and speciﬁcity for training and testing ranging from 80%
to 92%. In conclusion, DCEMRI in locally advanced breast cancer could
predict 5year survival in a small patient cohort. In addition, changes in
tumor vascularization after one cycle of NAC can be assessed.
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Paper IV
Diﬀusion weighted and dynamic contrast enhanced MRI in
evaluation of early treatment eﬀects during neoadjuvant chemo-
therapy in breast cancer patients.
The purpose of this study was to use MRI at 3 Tesla for early evalua-
tion of treatment eﬀects in breast cancer patients undergoing neoadjuvant
chemotherapy, and to identify MRI parameters that correlate to treatment
response. In addition, the reproducibility of diﬀusion weighted MRI was
assessed.
Diﬀusion weighted and dynamic contrast enhanced MRI of breast cancer pa-
tients were performed before and after the ﬁrst cycle of NAC. The apparent
diﬀusion coeﬃcient was calculated from the DWMRI, and the parameters
Ktrans and ve were calculated from twocompartment analysis of the DCE
MRI. ADC values from two baseline examinations prior to NAC were used
in a reproducibility analysis, and the intraclass correlation coeﬃcient (ICC)
was calculated. Changes in statistical features derived from the distributions
of MRI parameters, the tumor diameter and the volume after one cycle of
NAC was assessed. In addition, the same features were used as input for a
linear discriminant analysis (LDA) to ﬁnd the best predictors for pathologic
response.
The ADC values from two baseline examinations showed very good repro-
ducibility, with ICC ranging from 0.75  0.84. A reduction in both MRI
deﬁned longest tumor diameter and tumor volume were found after only
one cycle of NAC. In addition, the treatment resulted in increased ADC
mean, ADC maximum and ve mean, and a reduction in ve skewness. The
best predictors from the LDA among the baseline features were the entropy
and skewness of ve. After the ﬁrst treatment, the decrease in the longest
diameter measured on MRI was the best predictor of treatment response,
followed by mean and skewness of ADC, and Ktrans entropy.
ADC measurements were highly reproducible, and increased signiﬁcantly af-
ter only one cycle of NAC. The change in longest tumor diameter from DCE
MRI was the best predictor for tumor response, while changes in kinetic
parameters were more moderate. Further investigations on early evaluation
of treatment eﬀects should focus on a combination of change in DCEMRI
derived tumor size combined with changes in ADC after one cycle of NAC.
Chapter 5
Discussion and conclusion
5.1 Main ﬁndings
In this thesis, diﬀerent MR methods have been used to assess tumor prop-
erties and treatment eﬀects. The main focus has been on breast cancer,
however a xenograft study of colon cancer was performed initially, to estab-
lish MR protocols on the newly installed 7 Tesla animal scanner. In this
paper (Paper I), the growth of a colon cancer model was inhibited by the
synthetic fatty acid TTA, both in vitro and in vivo. The restricted tumor
growth inﬂuenced the microenvironment and vascularity, and diﬀerences be-
tween TTA tumors and control tumors were detected with DCEMRI. In
Paper II, the established MRI protocol was extended with in vivo MRS,
and used for the breast cancer xenograft models treated with docetaxel.
Kinetic analysis of DCEMRI revealed similar diﬀerences in vascularity be-
tween treated and control tumors as in Paper I. In addition, multivariate
analysis of both in vivo and ex vivo MRS found changes in the metabolic
pattern between treated and control tumors. For the clinical breast cancer
studies the pattern were more complex, however changes in vascularity were
detected using empirical analysis of DCEMRI after only one cycle of NAC,
as shown in Paper III. In addition, DCEMRI parameters were correlated
to overall survival. Multivariate analysis was also used to analyze the data,
and conﬁrmed the ﬁndings. In Paper IV, ADC values from DWMRI were
measured in addition to kinetic parameters from DCEMRI. After one cycle
of NAC the tumor size decreased and the ADC mean values increased for all
the patients. Overall, the MRmethods used in this thesis can detect treat-
ment eﬀects, both with DCEMRI, MRS and DWMRI. The methods used
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in the preclinical studies were transferred and used in the clinical studies.
5.2 Dynamic contrast enhanced MRI
DCEMRI has become a widely used tool for imaging of tumor vascularity.
The nature of the tumor vascular network is chaotic, highly permeable and
heterogeneous, thus designing MRI experiments sensitive to both structural
and functional properties may be a challenge. There are often conﬂicting
interests when deciding parameters for DCEMRI, on one side a high spa-
tial resolution is needed for imaging of heterogeneous tumors, while on the
other side, high temporal resolution is essential when studying contrast en-
hancement dynamics. In addition, adequate signal to noise ratio (SNR)
and suﬃcient dynamic range for signal intensity change after contrast agent
injection has to be ensured.
Gadodiamide (Omniscan) is a widely used contrast agent used in clinical con-
trast enhanced MR examinations, and was chosen for both the preclinical
and the clinical studies in this thesis. By choosing a commonly used con-
trast agent, results are easily comparable to other studies, and knowledge
from the preclinical studies can be transfered to the clinics. However, this
intermediate sized extracellular contrast agent is not optimal for imaging of
vascular properties. For measuring perfusion, a freely diﬀusible tracer would
be a better choice combined with pharmacokinetic analysis. On the other
side, to assess the permeability of blood vessels, a high molecular weight
tracer would be appropriate, with more speciﬁc leakage in tumor areas.
The choice of MR sequences for the preclinical studies were based on experi-
ments with phantoms and excess mice from the Department of Comparative
Medicine, NTNU. The protocol was also based on earlier studies on a Bruker
Biospec 24/40 2.35 Tesla magnet. A 2D spinecho sequence with short echo
time was chosen both for measuring precontrast T1values and for the dy-
namic sequence. Other sequences were also considered, as gradient echo
(FLASH), but SE was found to be more robust, and the signal equation is
simple (1.1). It has been shown later that the FLASH sequence implemented
at the 7 Tesla scanner is not optimal, and may not be used for quantiﬁca-
tion.1 Experiments with agarose phantoms were used to measure T1values
for diﬀerent concentrations, and to convert signal intensities from the SE
scan used in the dynamic sequence for calculation of T1values. In these ex-
1Huuse, E. M., unpublished work, Dept. of Circulation and Medical Imaging.
5.2. Dynamic contrast enhanced MRI 29
periments the volume coil was used to avoid sensitivity variations between
the phantoms, such that the signal intensity in the phantom without con-
trast agent could be used as precontrast value. As shown in Figure 5.1A,
the calculated T1values were in good agreement with the measured values.
Furthermore, the calculated relaxation rate (1/T1) showed a linear relation-
ship to the actual contrast agent concentration, and the relaxivity (r1) for
the contrast agent was estimated by linear regression to 4.5 (mMs)−1 (r2 =
0.995, Figure 5.1B). In Paper I and II, a literature value was used for the
contrast agent relaxivity, r1 = 3.6 (mMs)
−1 (Yankeelov et al., 2005). Stud-
ies have shown that the relaxivity for a contrast agent may vary between
diﬀerent tissues, buﬀers and temperatures (Xie et al., 2001).
Figure 5.1: Results from work with phantoms on 7 Tesla and 3 Tesla. (A) Measured
T1 using several TRvalues vs. calculated T1, and (B) contrast agent concentration
vs. calculated relaxation rate (1/T1) with linear regression curve from the 7 Tesla
scanner. (C) Measured T1 using four ﬂip angles vs. calculated T1, and (D) the
contrast agent concentration vs. relaxation rate (1/T1) with linear regression curve
from the clinical 3 Tesla scanner.
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In the preclinical studies, the DCEMRI sequence was analyzed both with
twocompartment kinetic modeling and empirical methods. The twocompart-
ment model was based on the consensus from Tofts et al. (1999), and the
terming of parameters was adapted from this paper. For the calculation
of contrast agent concentration, fast water exchange between tissue water
compartments was assumed, a phenomenon described by Donahue et al.
(1994). Water in tissue is distributed between intracellular, interstitial and
intravascular space, and is moving between them. The spaces may con-
tribute with diﬀerent MR properties, and the degree of water exchange is
deﬁned as the ratio of motion relative to the diﬀerence in relaxation rates
between the spaces. Although this topic is debated, a fast exchange regime is
often assumed with clinical relevant contrast agent doses, however this may
introduce a source of error to the calculations. Other methods for phar-
macokinetic analysis have also been proposed, as Brix et al. (1991) and Su
et al. (1994), with slightly diﬀerent conditions and parameters. However,
the consensus paper was chosen as a basis, to enable comparison with other
studies (Tofts et al., 1999). Furthermore, a global AIF was chosen of practi-
cal reasons, measured at our lab with similar mice. Individual AIF's should
optimally be used, however this is challenging and was not the main focus of
this work. Better temporal resolution could also improve the results, how-
ever for the tumor models, the enhancement curves is described well, with
several points at the initial increasing part.
For the clinical studies, a 3D FLASH sequence was used for DCEMRI. In
Paper III, MRI data from earlier examinations were analyzed, thus opti-
mization of the protocol was not a part of this thesis. For Paper IV the
MRI protocol was optimized with aim to improve the temporal resolution
compared to a standard clinical examination. In breast cancer patients it
is diﬃcult to deﬁne the tumor borders before injection of contrast agent,
thus imaging of the whole breast is necessary. The choice of MRI sequences
were based on standard protocols on the Trio 3 Tesla system, and reﬁned
through phantom measurements and imaging of healthy volunteers. The
3D FLASH sequence has several advantages including fast imaging, large
volume of interest, and high SNR. Furthermore, good agreement with the
theoretical signal equation was found when varying ﬂip angle and repeti-
tion time on the system. A short TR was chosen to reduce scan time, and
the ﬂip angle was calculated to be sensitive to T1changes in the actual
range (1.3). The echo time was chosen as short as possible to reduce T ∗2 
eﬀects. No standard sequence for T1measurement was available, and several
methods were tested with varying results. By using the FLASH sequence,
identical geometry with the DCEMRI were possible, and calculations of
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contrast agent concentration in each voxel were then simpliﬁed. The TR
was increased to increase SNR and increase TE to avoid negative fatshift
artifacts. Four ﬂip angles were chosen to increase the accuracy of the cal-
culations. Phantom studies from the 3 Tesla scanner were performed with
waterﬁlled tubes doped with diﬀerent concentrations of contrast agent. The
T1values from a T1measurement were compared to calculated T1values
from signal intensities in an image identical to the dynamic sequence, and a
nice agreement was found (Figure 5.1C). When comparing calculated relax-
ation rates (1/T1) with the actual contrast agent concentrations, there was
a linear relationship up to 0.4 mM (Figure 5.1D). The relaxivity of contrast
agent on 3 Tesla was estimated to r1 = 3.8 (mMs)
−1 from linear regression
(r2 = 0.996). This is in agreement with values from the manufacturer (3.9
(mMs)−1 at 0.5 Tesla, from the Product Characteristics of Omniscan, GE
Healthcare), and is identical to the relaxivity used for calculations in Paper
IV.
Pharmacokinetic analysis was implemented in Paper IV, using the same
principles as for the preclinical models. A population based arterial input
function previously published was used in the analysis (Fritz-Hansen et al.,
1996; Schmid et al., 2009), as signal from arteries in the DCEMRI were
diﬃcult to achieve. However, individual AIF measurements in the aorta
has previously been implemented for breast cancer DCEMRI (Port et al.,
2001).
5.3 Diﬀusion weighted MRI
Diﬀusion weighted MRI was implemented in the patient study protocol at
3 Tesla in Paper IV. The method used for imaging was a twicerefocused
spinecho sequence with EPI readout, designed to reduce spatial distor-
tions due to eddycurrents. Signal attenuation for low bvalues is expected
to be highly inﬂuenced by intravascular water and blood ﬂow, thus bvalues
close to zero was omitted. Diﬀusion of water in tissue may be of complex
character, as water is distributed in diﬀerent tissue compartments. Never-
theless, a monoexponential ﬁt was considered relevant, as signal from the
intravascular compartment was suppressed. The range of bvalues chosen
(b = 50  800 s/mm2) is in accordance with the recommendations for DW
MRI in oncologic imaging (Padhani et al., 2009). The diﬀusion time will
also inﬂuence the measured ADC values, depending on the range of the cor-
responding diﬀusion distance. In paper IV, the diﬀusion time was roughly
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estimated to 40 ms, giving a diﬀusion distance of 20 µm, which is of the
same magnitude as human cells. Changes in ADC values after treatment is
therefore assumed to reﬂect cellular changes, as cell damage.
DWMRI was also implemented on the preclinical scanner (7 Tesla) and
used for treatment monitoring of MCF7 xenografts.2 A diﬀusion weighted
spinecho sequence was used with EPI readout as described by Stejskal and
Tanner (1965), with bvalues in the range 01000 s/mm2. The diﬀusion time
was 14 ms, giving a diﬀusion distance of 13 µm, also of the same magnitude
as the cell size.
5.4 MR spectroscopy
The PRESS sequence for in vivo MRS at 7 Tesla adapted a clinical relevant
echo time for breast cancer to reduce signal from fatty acids (TE = 135 ms).
However, this was reduced in later work with MCF7 xenograft tumor mod-
els, as there was very little signal from fatty acids.2 The PRESSsequence
has limitations in choice of low TEvalues, but higher SNR compared to e.g.
the Stimulated Echo Acquisition Mode (STEAM). This sequence is suitable
for experiments with low TE, however this was not emphasized in this study.
For the HR MAS MRS study, the pulse acquired spectra were not dominated
by signals from fatty acids, and were used in the analysis.
The MR spectra in Paper II were analyzed using multivariate methods. One
of the advantages with such methods is the ability to analyze all data in one
operation, and to extract important features from complex data. These
methods are not quantitative, thus only relative content and variation in
metabolites can be assessed. Both the unsupervised method PCA and the
supervised method PLS were used to analyze spectra. A careful selection
of the spectrum region of interest and mean normalization were done to
form a good basis for the analysis, however other choices may yield other
results. Generally, preprocessing of data is important when using multivari-
ate analysis, as diﬀerences in SNR and large variation in signals between
samples may contribute to the result. Work has been done to implement
absolute quantiﬁcation both in vivo and ex vivo with internal or external
standards. In high resolution MRS of solutions, quantiﬁcation is routinely
done, however for tissue samples the concentration of internal standards has
2EM Huuse, LR Jensen et al. Monitoring docetaxel response in MCF7 xenografts
using multimodal in vivo and ex vivo magnetic resonance methods, histopathology, and
gene expression. Submitted 2009
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to be assumed, and external standards may bind to proteins or structures
in tissue. The method ERETIC was developed for in vivo quantiﬁcation of
MRS by Barantin et al. (1997), and this method has been implemented for
HR MAS MRS the last years (Sitter et al., 2010). However, this method
was not implemented for the experiments in Paper II.
5.5 Tumor model systems
In this thesis, model systems were used to assess tumor characteristics and
therapy induced changes. The use of xenografts may be a powerful tool
in cancer research, and mimics the whole tumor system, in contrast to cell
cultures. The tumors in a xenograft study are very similar, which increases
the power of the studies. In addition, the tumors grow fast, and optimiza-
tion of treatment regimens and timing of the experiments may be carefully
designed. For MRI and MRS, the availability of higher ﬁeld strengths and
smaller volumes of interest is a great advantage. However, care has to be
taken when translating results to the clinics. The properties of the injected
human tumor cells are retained, but the stroma, including the blood vessels,
are from the host. Complex interactions between cancer cells and stroma are
contributing to the development of tumors. Neoangiogenesis is crucial for
invasive growth and tumor development (Vargo-Gogola and Rosen, 2007),
thus the assessment of tumor vascularity might not be directly transferable
to the clinics. However, subcutaneously tumor models were established in
Paper I and II to implement MR protocols for the assessment of treatment
response. To reﬂect the great biological diversity in a patient population,
the MR methods should be implemented for other tumor models. Studies
of gene expression proﬁles in breast cancer biopsies suggest at least ﬁve dis-
tinct diseases, with diﬀerent treatment response and prognosis (Perou et al.,
2000; Sørlie et al., 2003). Two of these are established as orthotopic tumor
models and are currently being used with the MRmethods implemented in
this thesis (Bergamaschi et al., 2009; Huuse et al., 2009) .
Several conditions have to be considered when comparing animal studies to
clinical studies. In this thesis, the imaging of the breast cancer xenografts
was done only three days after the administration of chemotherapy. In
patients, the imaging is of practical reasons usually done three weeks after
chemotherapy, at the timing of the next treatment cycle. DCEMRI of the
tumor models detected changes after treatment, although the parameters
related to vascularity increased, while in many clinical studies of treatment
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response a decrease in these parameters are often detected (Pickles et al.,
2005; Ah-See et al., 2008). This could be explained by the timing of the
imaging. However, despite the limitations, MRI and MRS of tumor models
is a powerful tool for understanding response mechanisms of chemotherapy,
and also to develop methods transferable to the clinics.
5.6 Assessment of treatment response
During the administration of NAC to breast cancer patients the tumor re-
sponse can be monitored in situ, a great advantage to adjuvant therapy
where the primary tumor is resected. MRI is a powerful tool for this task,
and has been shown superior for monitoring of treatment when compared to
clinical evaluation, mammography and ultrasound (Zakhireh et al., 2008).
Currently, MRI is recommended as a tool for evaluation of treatment re-
sponse halfway during treatment in the guidelines from the European Society
of Breast Imaging (Mann et al., 2008). However, early treatment evaluation
with functional MRI is a ﬁeld that still needs validation.
Results from the DCEMRI experiments in the preclinical studies showed
diﬀerences in vascular parameters between treated and control tumors. The
shift in the distributions to higher values could be explained by reduced pro-
liferation for the treated tumors, leading to an increased EES and vascular
surface area. Numerous preclinical studies have used DCEMRI to assess
tumor vascularity, of colon (de Lussanet et al., 2003), melanoma (Benjamin-
sen et al., 2004) and breast (Dadiani et al., 2004) as examples. With the
development of new vascular targeted therapies, DCEMRI is a valuable tool
for treatment monitoring and understanding therapeutic eﬀects (Checkley
et al., 2003; McIntyre et al., 2004; de Lussanet et al., 2004). DCEMRI
uses signal intensity change caused by indirect eﬀects of a contrast agent to
assess vascularity, which is often indirectly aﬀected by chemotherapy. Thus
this might be a more important tool for monitoring antiangiogenic agents,
that more directly aﬀects the vascular system of tumors. Nevertheless, ther-
apy of tumors in general will inﬂuence the vascularity, directly or indirectly,
and the observed eﬀects could also be vascular normalization, which would
beneﬁt further treatment (Jain, 2005). In the colon cancer xenograft study,
diﬀerences in vascularity were also detected with DCEMRI, showing the
diversity of mechanisms inﬂuencing neoangiogenesis, and that the method
can be used in several model systems.
Several clinical studies of NAC in breast cancer have used DCEMRI to
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assess early treatment eﬀects. An accurate measurement of change in tumor
size is an important measure for response, in addition to a valuable tool
for distinguishing between malign and benign disease of the breast (Kuhl,
2000). The MRI measured tumor size or volume from DCEMRI has shown
good correlation to pathologic measured tumor size. The decrease in MRI
measured tumor size was the most signiﬁcant change after only one cycle
of NAC in the clinical studies, however no signiﬁcant diﬀerence was seen
between responders and nonresponders. In addition to tumor size, quanti-
tative vascular or empirical parameters have been investigated as predictive
parameters to response, however the results are diverse. Some ﬁnd a clear
correlation of kinetic parameters to response (Pickles et al., 2005; Ah-See
et al., 2008; Wasser et al., 2003), while others show more moderate results
(Padhani et al., 2006; Loo et al., 2008). In Paper III, a decrease in RSI and
AUC were found for responders after only one cycle, which can be explained
as reduced perfusion in tumor as an indirect eﬀect of treatment. In Paper IV
an increase in ve was found for all patients after treatment which is similar
to the results in the preclinical studies. This could also be interpreted as
increased EES after cell death. For an overview of selected publications on
early treatment evaluation with MRI, see Table 5.1. Large variation can
be found in study design, MR system used, imaging methods and analysis
methods. There are also variations in the deﬁnition of response, from clin-
ical evaluation to pathologic conﬁrmed response, and this will have a great
impact on the results in the diﬀerent studies.
DWMRI was used for treatment monitoring in the clinical study, and also
in MCF7 xenografts as shown in Figure 5.2. Three days after treatment
with docetaxel the ADC median values increased signiﬁcantly compared to
control tumors. Measurement of water diﬀusion during therapy has been
proposed as a more direct measure of treatment response, as diﬀusivity is
restricted by e.g cell membranes, and may be correlated to cellularity (Lyng
et al., 2000). Thus the increase in ADC may be explained as degradation
of cell membranes due to cell death, and reduced cell density caused by
inhibition of proliferative cells.
DWMRI of breast cancer patients also showed a signiﬁcant increase in ADC
values after treatment (Paper IV). This result is in agreement with other
published studies, that also propose a correlation to degree of tumor response
(Pickles et al., 2006; Sharma et al., 2008; Iacconi et al., 2009). As for the
preclinical study (Figure 5.2) the ADC measurements reﬂects direct eﬀects
as cell damage and death after chemotherapy. Despite challenging imaging
of the breast with EPI sequences sensitive for eddy current artifacts and fat
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Figure 5.2: A, Progress in median ADC 1 day before treatment and 1, 3, and 6 days
post treatment. # signiﬁcantly diﬀerent (Dunnet) compared to before treatment, *
signiﬁcant diﬀerence (ttest) between treated and control on the same day. B and
C: ADC maps from a control tumor and a treated tumor 1 day before treatment
and 3 days posttreatment. Note the higher ADC values in the treated tumor.
From Huuse, Jensen et al., submitted 2009
shift, this seems like a promising tool for evaluating treatment response in
breast tumors.
MRS is a promising method for monitoring metabolism in vivo at the same
session as MRI. In the preclinical study of MCF7 xenografts in Paper II, a
change in the metabolic proﬁle after docetaxel treatment was demonstrated,
both with in vivo MRS and ex vivo HR MAS MRS of the same tumor sam-
ples. Relatively lower signals from choline compounds were detected for
the treated tumors, and can be explained by reduced proliferative activity,
reduced cell density and increased cell death. These results are in agree-
ment with other studies, where the choline metabolism has been of special
interest with respect to tumor progression, proposing choline compounds as
biomarkers both for malignancy and treatment eﬀect (Eliyahu et al., 2007;
Sitter et al., 2006; Glunde et al., 2006). MRS is a powerful tool with possibil-
ities for longitudinal studies, quantiﬁcation and for understanding response
mechanisms. This has been and are further studied in our research group
(Bathen et al., 2007; Bakken et al., 2001; Cao et al., 2009).
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5.7 DCEMRI and prognosis
A strong prognostic factor for breast cancer patients with primary inop-
erable disease is a complete pathologic response after NAC. MRI derived
parameters may also be correlated to survival in this patient group, and was
assessed in Paper III. Only a few additional studies with this focus have been
published, and they all report a correlation between contrast enhancement
parameters and survival (Pickles et al., 2008; Boné et al., 2003). Gener-
ally, patients with large tumors and high degree of contrast enhancement
will be expected to have shorter overall survival. Both Paper III and an
extended study of the patient cohort3 showed that a higher pretreatment
contrast enhancement as assessed with RSI or curve types was correlated to
poorer prognosis. This conﬁrmed previous ﬁndings by Pickles et al. (2008),
where both tumor volume and enhancement parameters were found to cor-
relate to overall survival. In a study by Boné et al. (2003), patients with
primary malignancy were examined preoperatively, resulting in a diﬀerent
patient population than the other studies. However, despite poor tempo-
ral resolution (6 minutes), the ﬁndings were similar showing high contrast
enhancement and larger tumor volumes for patients with shorter survival.
At the time of diagnosis a long process of tumor progression has formed
the individual patient's cancer disease, and the tumor characteristics at this
time point are the basis for evaluating patients' prognosis. One of the most
important steps in tumor progression is the neoangigenic switch. When
the tumor adapts the ability to initiate neoangiogenesis, blood vessels will
supply the tumor cells, and one important premise for metastatic ability is
ensured. Highly proliferative and aggressive tumors are often highly vascu-
larized, and associated with high degree of contrast enhancement. Thus, in
vivo measurements of the angiogenic conditions in tumors could contribute
to each patients prognosis, as measured by DCEMRI (Jensen et al., 2009).
DWMRI could also play an important role as prognostic factor in breast
cancer, and is an interesting topic for future studies.
3MG Heldahl et al. Prognostic value of pretreatment dynamic contrastenhanced MR
imaging in locally advanced breast cancer: overall survival predicted from single voxel
classiﬁcation of signal intensity time course data. Submitted 2009
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5.8 Conclusion and future perspectives
In this thesis, MR protocols for assessing treatment eﬀects in both pre
clinical and clinical studies have been established. The MR methods were
DCEMRI with pharmacokinetic analysis, DWMRI, in vivo MRS and ex
vivo HR MAS MRS. Diﬀerences in tumor vascularity were detected with
DCEMRI, both in breast cancer xenografts treated with docetaxel and in
colon cancer xenografts inﬂuenced by the dietary fatty acid TTA. In breast
cancer patients with locally advanced disease, changes in vascularity were
also observed after only one cycle of NAC, although the pattern here were
more diﬀuse. A correlation between DCEMRI before treatment and sur-
vival was found for the same patient group. Furthermore, ADC parameters
calculated from DWMRI was signiﬁcantly increased after therapy, both for
MCF7 xenografts and for breast cancer patients. This could be a powerful
measure for tumor response, more directly related to treatment eﬀects com-
pared to DCEMRI. Diﬀerences in metabolism were seen with MRS in the
breast cancer xenografts, with a relative decrease in choline compounds as
the most dominating change.
For preclinical studies, MRI and MRS will still play an important role
in characterizing tumor models and understanding mechanisms of therapy.
The work with tumor model systems has developed in our research group,
to new orthotopic breast cancer models. With the basis of the MR pro-
tocols presented in this thesis, these model systems are now being used to
investigate new treatment regimes, as antiangiogenic therapies. By using
several tumor models, the diversity in human tumors can be elucidated, and
further studies of the variation in treatment response between apparently
similar tumors can be performed. The unique possibility for combining sev-
eral MR methods during one examination may provide an important tool in
evaluation of complex treatment eﬀects in these tumor model systems.
For clinical MRI of breast cancer, derived parameters may be potential
biomarkers for more individualized therapy, however this must be further
explored to enhance sensitivity and speciﬁcity. Studies that investigate the
reproducibility of DCEMRI parameters have been published (Ah-See et al.,
2008), however this should be done in a larger scale to adjust the clinical
value of the method as a routine diagnostic tool. The trend moves toward
using higher ﬁeld strengths both for research and in the clinics, although
the impact on sensitivity and speciﬁcity for both diagnosis and assessment
of treatment response is not clear. This will among other factors depend
on how the increased SNR is used, like improved temporal or spatial res-
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olution in DCEMRI. Studies addressing these questions would be highly
relevant, as comparing 1.5 Tesla versus 3 Tesla in clinical trials. In addition,
the use of combined sequences that can reconstruct both high temporal and
high spatial resolution data from the same MRI acquisition has also evolved
as promising (Han et al., 2008), although the quantitative reliability from
these acquisitions should be compared to standard measurements. Several
large multicenter trials are ongoing and are including breast cancer patients
scheduled for NAC, as the ACRIN and MARIBS trials (Mann et al., 2008).
DCEMRI is performed before and after two cycles of treatment, and the re-
sults will be valuable for the future use of DCEMRI in assessment of locally
advanced breast cancer. For DWMRI, including this acquisition in stan-
dard breast MRI may increase the information from the examinations. The
use of ADC values in treatment monitoring seems feasible, however more
investigations should be done to increase the knowledge of this promising
parameter. Comparisons between systems and diﬀerent methods need to be
done, and improvements on imaging methods to increase SNR and decrease
slice thickness should be prioritized.
The clinical studies designed today will be relevant for several years, when
overall survival and disease free survival can be assessed. Thus providing
high quality MRI data today is of great importance, such that new prognostic
markers for locally advanced breast cancer can be established.
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